Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Despite having the fastest supercomputer in pharma and potential $20 billion in milestones from big pharma collaborations, Recursion's AI-generated assets have yet to impress. The company’s pipeline ...

The CEO has set a high bar for the business, and if it hits it, the stock could easily 10x in value. Investing in growth stocks can lead to significant returns for investors in the long run. But ...

Whenever machine learning is applied to a given field of industry, defining the objective is one of the most salient questions. Just what are you trying to find out? In the biological sciences, that ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Getting in on the ground floor would be great, but only if there's massive upside ahead for the company. Several stocks on the market offer investors the opportunity to capitalize on the rapidly ...